Kirkland Advises Bristol Myers Squibb on Acquisition of Mirati Therapeutics for up to $5.8 Billion

Retrieved on: 2023-10-08 22:55:08

Tags for this article:

Click the tags to see associated articles and topics

Kirkland Advises Bristol Myers Squibb on Acquisition of Mirati Therapeutics for up to $5.8 Billion. View article details on hiswai:

Excerpt

... biotechnology company Mirati Therapeutics (NASDAQ:MRTX). The transaction was announced October 8, 2023. The deal has been unanimously approved by ...

Article found on: www.kirkland.com

View Original Article